Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Efficacy and Safety of FLOT Plus Durvalumab as Neoadjuvant Therapy Followed by TS-1 Plus Durvalumab as Adjuvant Therapy in Resectable Gastric Cancer (DURATION-GC)

NCT07757191 is registered in ClinicalTrials.gov with Taipei Veterans General Hospital, Taiwan as lead sponsor.

NCT NCT07757191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07757191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Efficacy and Safety of FLOT Plus Durvalumab as Neoadjuvant Therapy Followed by TS-1 Plus Durvalumab as Adjuvant Therapy in Resectable Gastric Cancer (DURATION-GC)
Lead sponsor
Taipei Veterans General Hospital, Taiwan
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
October 31, 2029
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable gasrtic cancer